Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Nature|April 15, 2026
Prospective evaluation of genomics-guided off-label treatmentK Verkerk, A C Spiekman, S F Haj Mohammad, et al.
Ebiomedicine|March 19, 2025
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumoursChiel F Ebbelaar, Anne M L Jansen, Leonie C M Speet, et al.
Gastroenterology|May 15, 2018
Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2Sanne W Ten Broeke, Tom C van Bavel, Anne M L Jansen, et al.
ESMO Open|January 8, 2025
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)K Verkerk, L J Zeverijn, J van de Haar, et al.
Molecular Oncology|January 31, 2025
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnosticsGuy Froyen, Pieter-Jan Volders, Ellen Geerdens, et al.
International Journal of Cancer|October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocolIlse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2026
BRAF<sup>V600E</sup>-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery ProtocolSoemeya F Haj Mohammad, Ilse A C Spiekman, Karlijn Verkerk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery ProtocolKarlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor TypesHanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancerJ M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Pageof 5